Literature DB >> 27826640

Role of YAP/TAZ transcriptional regulators in resistance to anti-cancer therapies.

Min Hwan Kim1, Joon Kim2.   

Abstract

A diverse range of drug resistance mechanisms in cancer cells and their microenvironment significantly reduces the effectiveness of anti-cancer therapies. Growing evidence suggests that transcriptional effectors of the Hippo pathway, YAP and TAZ, promote resistance to various anti-cancer therapies, including cytotoxic chemotherapy, molecular targeted therapy, and radiation therapy. Here, we overview the role of YAP and TAZ as drug resistance mediators, and also discuss potential upstream regulators and downstream targets of YAP/TAZ in cancer. The widespread involvement of YAP and TAZ in resistance mechanisms suggests that therapeutic targeting of YAP and TAZ may expedite the development of effective anti-resistance therapies.

Entities:  

Keywords:  Biomarker; Drug; Hippo pathway; Resistance; TAZ; YAP

Mesh：

Substances：

Year:  2016        PMID： 27826640     DOI： 10.1007/s00018-016-2412-x

Source DB:  PubMed          Journal:  Cell Mol Life Sci        ISSN： 1420-682X            Impact factor:   9.261


  164 in total

1.  Improved overall survival in melanoma with combined dabrafenib and trametinib.

Authors:  Caroline Robert; Boguslawa Karaszewska; Jacob Schachter; Piotr Rutkowski; Andrzej Mackiewicz; Daniil Stroiakovski; Michael Lichinitser; Reinhard Dummer; Florent Grange; Laurent Mortier; Vanna Chiarion-Sileni; Kamil Drucis; Ivana Krajsova; Axel Hauschild; Paul Lorigan; Pascal Wolter; Georgina V Long; Keith Flaherty; Paul Nathan; Antoni Ribas; Anne-Marie Martin; Peng Sun; Wendy Crist; Jeff Legos; Stephen D Rubin; Shonda M Little; Dirk Schadendorf
Journal:  N Engl J Med       Date:  2014-11-16       Impact factor: 91.245

2.  YAP Drives Growth by Controlling Transcriptional Pause Release from Dynamic Enhancers.

Authors:  Giorgio G Galli; Matteo Carrara; Wei-Chien Yuan; Christian Valdes-Quezada; Basanta Gurung; Brian Pepe-Mooney; Tinghu Zhang; Geert Geeven; Nathanael S Gray; Wouter de Laat; Raffaele A Calogero; Fernando D Camargo
Journal:  Mol Cell       Date:  2015-10-01       Impact factor: 17.970

3.  Hippo pathway activity influences liver cell fate.

Authors:  Dean Yimlamai; Constantina Christodoulou; Giorgio G Galli; Kilangsungla Yanger; Brian Pepe-Mooney; Basanta Gurung; Kriti Shrestha; Patrick Cahan; Ben Z Stanger; Fernando D Camargo
Journal:  Cell       Date:  2014-06-05       Impact factor: 41.582

4.  Transduction of mechanical and cytoskeletal cues by YAP and TAZ.

Authors:  Georg Halder; Sirio Dupont; Stefano Piccolo
Journal:  Nat Rev Mol Cell Biol       Date:  2012-08-16       Impact factor: 94.444

5.  Regulation of insulin-like growth factor signaling by Yap governs cardiomyocyte proliferation and embryonic heart size.

Authors:  Mei Xin; Yuri Kim; Lillian B Sutherland; Xiaoxia Qi; John McAnally; Robert J Schwartz; James A Richardson; Rhonda Bassel-Duby; Eric N Olson
Journal:  Sci Signal       Date:  2011-10-25       Impact factor: 8.192

6.  Mst1 and Mst2 maintain hepatocyte quiescence and suppress hepatocellular carcinoma development through inactivation of the Yap1 oncogene.

Authors:  Dawang Zhou; Claudius Conrad; Fan Xia; Ji-Sun Park; Bernhard Payer; Yi Yin; Gregory Y Lauwers; Wolfgang Thasler; Jeannie T Lee; Joseph Avruch; Nabeel Bardeesy
Journal:  Cancer Cell       Date:  2009-11-06       Impact factor: 31.743

7.  Hippo-independent activation of YAP by the GNAQ uveal melanoma oncogene through a trio-regulated rho GTPase signaling circuitry.

Authors:  Xiaodong Feng; Maria Sol Degese; Ramiro Iglesias-Bartolome; Jose P Vaque; Alfredo A Molinolo; Murilo Rodrigues; M Raza Zaidi; Bruce R Ksander; Glenn Merlino; Akrit Sodhi; Qianming Chen; J Silvio Gutkind
Journal:  Cancer Cell       Date:  2014-05-29       Impact factor: 31.743

8.  TAZ is required for metastatic activity and chemoresistance of breast cancer stem cells.

Authors:  M Bartucci; R Dattilo; C Moriconi; A Pagliuca; M Mottolese; G Federici; A Di Benedetto; M Todaro; G Stassi; F Sperati; M I Amabile; E Pilozzi; M Patrizii; M Biffoni; M Maugeri-Saccà; S Piccolo; R De Maria
Journal:  Oncogene       Date:  2014-02-17       Impact factor: 9.867

9.  Insulin-like growth factor (IGF) signaling in tumorigenesis and the development of cancer drug resistance.

Authors:  Sahitya K Denduluri; Olumuyiwa Idowu; Zhongliang Wang; Zhan Liao; Zhengjian Yan; Maryam K Mohammed; Jixing Ye; Qiang Wei; Jing Wang; Lianggong Zhao; Hue H Luu
Journal:  Genes Dis       Date:  2015-03-01

10.  Yes-associated protein (YAP) modulates oncogenic features and radiation sensitivity in endometrial cancer.

Authors:  Masahiro Tsujiura; Virginia Mazack; Marius Sudol; Hanna G Kaspar; John Nash; David J Carey; Radhika Gogoi
Journal:  PLoS One       Date:  2014-06-27       Impact factor: 3.240
View more
  38 in total

1.  Genome-wide RNA interference screening reveals a COPI-MAP2K3 pathway required for YAP regulation.

Authors:  Yong Joon Kim; Eunji Jung; Eunbie Shin; Sin-Hyoung Hong; Hui Su Jeong; Gayeong Hur; Hye Yun Jeong; Seung-Hyo Lee; Ji Eun Lee; Gun-Hwa Kim; Joon Kim
Journal:  Proc Natl Acad Sci U S A       Date:  2020-08-03       Impact factor: 11.205

2.  TRIB3 confers radiotherapy resistance in esophageal squamous cell carcinoma by stabilizing TAZ.

Authors:  Sha Zhou; Shiliang Liu; Chuyong Lin; Yue Li; Liping Ye; Xianqiu Wu; Yunting Jian; Yuhu Dai; Ying Ouyang; Lei Zhao; Mengzhong Liu; Libing Song; Mian Xi
Journal:  Oncogene       Date:  2020-03-10       Impact factor: 9.867

Review 3.  Regulation of the Hippo pathway in cancer biology.

Authors:  Sungho Moon; So Yeon Park; Hyun Woo Park
Journal:  Cell Mol Life Sci       Date:  2018-03-30       Impact factor: 9.261

Review 4.  Cancer invasion into musculature: Mechanics, molecules and implications.

Authors:  Lianne Beunk; Kari Brown; Iris Nagtegaal; Peter Friedl; Katarina Wolf
Journal:  Semin Cell Dev Biol       Date:  2018-09-05       Impact factor: 7.727

Review 5.  A time for YAP1: Tumorigenesis, immunosuppression and targeted therapy.

Authors:  Masahiro Shibata; Kendall Ham; Mohammad Obaidul Hoque
Journal:  Int J Cancer       Date:  2018-07-24       Impact factor: 7.396

6.  Correlating Chemical Sensitivity with Low Level Activation of Mechanotransduction Pathways in Hematologic Malignancies.

Authors:  Robert G Hawley
Journal:  Explor Res Hypothesis Med       Date:  2017-09-11

Review 7.  The STK38-XPO1 axis, a new actor in physiology and cancer.

Authors:  Alexandre Pj Martin; Vasily N Aushev; Gérard Zalcman; Jacques H Camonis
Journal:  Cell Mol Life Sci       Date:  2020-11-03       Impact factor: 9.261

8.  RASAL2 Confers Collateral MEK/EGFR Dependency in Chemoresistant Triple-Negative Breast Cancer.

Authors:  Siang-Boon Koh; Kenneth Ross; Steven J Isakoff; Nsan Melkonjan; Lei He; Karina J Matissek; Andrew Schultz; Erica L Mayer; Tiffany A Traina; Lisa A Carey; Hope S Rugo; Minetta C Liu; Vered Stearns; Adam Langenbucher; Srinivas Vinod Saladi; Sridhar Ramaswamy; Michael S Lawrence; Leif W Ellisen
Journal:  Clin Cancer Res       Date:  2021-06-24       Impact factor: 12.531

9.  Blocking circ_0014130 suppressed drug resistance and malignant behaviors of docetaxel resistance-acquired NSCLC cells via regulating miR-545-3p-YAP1 axis.

Authors:  Dongjie Du; Xiaoci Cao; Xinbo Duan; Xianbo Zhang
Journal:  Cytotechnology       Date:  2021-05-25       Impact factor: 2.040

Review 10.  Reactive Oxygen Species and Mitochondrial Dynamics: The Yin and Yang of Mitochondrial Dysfunction and Cancer Progression.

Authors:  Jan Ježek; Katrina F Cooper; Randy Strich
Journal:  Antioxidants (Basel)       Date:  2018-01-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.